GlassScriptPhysician profile
Vandana A Patel
NPI 1306847652
$2,157.54
in general payments reported to CMS, 2019-2025
31 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $123 · 2021: $232 · 2022: $335 · 2023: $476 · 2024: $91.36 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.96 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $302.20 | 2019-2023 | Nucala |
| Astrazeneca Pharmaceuticals LP | $187.83 | 2019-2023 | Breztri |
| Genentech, INC. | $180.52 | 2025 | Xolair |
| Kaleo, INC. | $142.49 | 2023-2024 | Auvi-Q |
| Baxter Healthcare | $125.04 | 2022-2023 | |
| Mylan Specialty L.P. | $124.83 | 2019-2023 | Yupelri |
| Madrigal Pharmaceuticals | $113.94 | 2025 | Rezdiffra |
| Genentech USA, INC. | $96.07 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.69 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $76.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $76.24 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.54 | 2022-2023 | Glassia |
| Genzyme Corporation | $60.89 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Insmed, INC. | $48.74 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $46.58 | 2022 | |
| Philips North America LLC | $43.91 | 2019 | |
| Grifols USA, LLC | $42.92 | 2019 | |
| Electromed, INC. | $41.28 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $29.08 | 2023 | Purified Cortrophin Gel |
| Circassia INC. | $27.58 | 2019 | |
| Nestle Healthcare Nutrition INC. | $24.11 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.97 | 2020 | |
| Resmed Corp | $19.53 | 2019 | |
| Shire North American Group INC | $19.44 | 2019 | |
| Pharming Healthcare, INC. | $18.76 | 2022 | |
| Portola Pharmaceuticals, LLC | $17.24 | 2019 | |
| Gilead Sciences, INC. | $15.42 | 2019 | |
| Astellas Pharma US INC | $15.36 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.35 | 2020 | |
| Advanced Respiratory, INC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandana Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.